Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin Extended Treatment in Idiopathic Purulent Oedematous Sinusitis
2020-001227-13Phase 3Active
- Sponsor
- Centre Hospitalier Intercommunal de Créteil
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rhinosinusitis and bacterial rhinosinusitis comparing Azithromycin extended treatment with Placebo (2 arms). Primary endpoint: Primary: SNOT-22 score at 3 months. Started Nov 2021; status: active.
02
Drugs
azithromycin
03
Conditions
rhinosinusitisbacterial rhinosinusitis
Beyond the preview
Go deeper on 2020-001227-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001227-13.